Financial Data and Key Metrics Changes - The company reported Q2 revenue of $621 million, bringing the first half total to $1.2 billion, with changes attributed to the ScholarOne divestiture and business disposals, partially offset by organic growth and foreign exchange [23] - The second quarter net loss was $72 million, an improvement over the previous year due to the absence of a non-cash impairment charge recorded last year [24] - Adjusted diluted EPS was $0.18, with changes attributed to divestitures and disposals [24] - Free cash flow was strong at $50 million for Q2 and $161 million for the first half, driven by adjusted EBITDA despite higher one-time costs associated with the value creation plan [28][29] - The mix of organic recurring revenue to total revenue for the first half improved to 88%, an increase of 800 basis points compared to last year [21] Business Line Data and Key Metrics Changes - The A and G business delivered 2% organic ACV and subscription revenue growth, with a 96% renewal rate achieved [7][11] - The IP segment returned to organic growth in patent annuities, with recurring revenue rising by about 1.5% in the first half of 2025 [15] - Life Science and Healthcare segment saw a return to organic ACV growth, supported by investments in the Cortellis suite of products [18][70] Market Data and Key Metrics Changes - The company noted a market-wide surge in AI innovation, which is expected to drive growth in the patent renewal business [15] - The U.S. dollar weakened against foreign currencies, providing a foreign exchange translation tailwind on revenue and adjusted EBITDA [26][28] Company Strategy and Development Direction - The value creation plan (VCP) is on track, with measurable progress across key initiatives and KPIs, including AI-led product innovation and operational efficiency [5][8] - The company is transitioning away from transactional sales to increase recurring revenue, with A and G subscription revenue now constituting 93% of total segment revenue [10][11] - A strategic review is underway to assess alternatives across the business, with results expected to be communicated in February 2026 [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the renewal rates and subscription uptake despite macroeconomic challenges, highlighting the mission-critical nature of their products [61] - The company anticipates continued organic growth in the second half of the year, driven by improvements in the A and G and Life Sciences segments [39] - Management noted that the strategic disposals are expected to lower revenue by approximately $125 million this year, but are part of optimizing the business model [35] Other Important Information - The company announced the appointment of Maroon Murad as President of the IP segment, effective September 8, 2025 [17] - The company has completed refinancing $500 million of its 2026 bonds, extending the maturity by five years [30] Q&A Session Summary Question: Rebound in the IP business and AI opportunities - Management noted that new patent filings take a few years to impact renewals, but the trend of increased AI-related patents is expected to benefit the business globally over the next few years [44][46] Question: Potential changes to the U.S. patent fee structure - Management stated that they are well-positioned to support any changes in the IP ecosystem due to their long-standing presence and collaboration with patent offices and law firms [51][52] Question: University funding cuts and renewal outlook - Management reported strong renewal rates and emphasized the critical nature of their products to universities, indicating confidence in continued renewals [61] Question: Sales momentum and new sales incentive plan - Management highlighted the focus on subscription and recurring revenue, noting positive sales momentum and excitement within the sales organization [66] Question: Market dynamics in Life Sciences and Healthcare - Management indicated stable R&D spending and improvements in the subscription business, attributing growth to investments in the Cortellis suite [71] Question: Delays in disposals - Management explained that one disposal is taking longer due to customer requests for more time to adjust to alternative offerings [76]

Financial Performance - H1 2025 revenue reached €3677 million, a 70% increase at constant currency (cc)[14] - H1 2025 adjusted EBITDA was €876 million, up 127% cc[14] - Free cash flow pre-M&A for H1 2025 was -€14 million, an improvement of €182 million compared to H1 2024[-196 million][14] - The leverage ratio decreased to 42x in H1 2025, compared to 46x at the end of FY24[14] Business Segment Performance - Biopharma revenue grew by 82% cc in H1 2025[17] - Diagnostic revenue increased by 28% cc in H1 2025[23] Margin Expansion - Adjusted EBITDA margin increased by 80 bps in H1 2025, despite the IRA impact[17] - Like-for-like adjusted EBITDA margin increased by 171 bps in H1 2025[17] Capital Allocation - An interim dividend of €015 per share was reinstated[14] - Liquidity stands at €14 billion[43] Future Outlook - The company reaffirmed its 2025 guidance and improved its free cash flow pre-M&A guidance to €375 - €425 million[47]

Core Insights - Clarivate Plc reported a total revenue of $593.7 million for Q1 2025, a decrease of 4.4% from $621.2 million in Q1 2024, primarily due to inorganic divestitures and foreign currency translation impacts [2][7] - The company experienced a net loss of $103.9 million, compared to a net loss of $75.0 million in the same quarter of the previous year [3][6] - Adjusted net income for Q1 2025 was $95.8 million, unchanged on a per share basis at $0.14 compared to Q1 2024 [3][32] Financial Performance - Organic revenues increased by 0.3% in Q1 2025, driven by a 0.6% increase in organic recurring revenues, while organic transactional revenues decreased [2][8] - Subscription revenues fell by 3.6% to $388.6 million, largely due to the divestiture of the ScholarOne product group [7][27] - Operating cash flow was $171.2 million, down from $176.2 million in the prior year, while free cash flow decreased slightly to $110.3 million [4][10] Strategic Initiatives - The CEO highlighted improved sequential organic Annual Contract Value (ACV) growth due to higher renewals and new business wins, emphasizing the effectiveness of the Value Creation Plan [5][11] - The company reaffirmed its full-year 2025 outlook, projecting organic ACV growth of 1.0% to 2.0% and total revenues between $2.28 billion and $2.40 billion [12][14] Balance Sheet and Cash Flow - As of March 31, 2025, cash and cash equivalents increased to $354.0 million, while total debt remained stable at $4,570.8 million [9][10] - The company repurchased $50 million of ordinary shares as part of its capital allocation strategy [4][11] Revenue Breakdown - Recurring revenues, which include subscription and re-occurring revenues, saw a slight organic increase of 0.6%, while transactional revenues dropped by 14.2% [8][27] - The decline in total ACV was primarily attributed to the divestiture of the ScholarOne product group and the wind-down of certain product lines [25][27]

Financial Data and Key Metrics Changes - In Q3 FY 2025, net sales increased by 4% year-over-year, with volume growth of 9% as the company rebuilt after transitioning to a new ERP system [12][26] - Adjusted EBITDA grew by 6%, reaching $364 million, primarily due to higher sales volumes and lower manufacturing costs [31][32] - Price mix declined by 5% compared to the prior year quarter due to planned investments in pricing to remain competitive [27][32] Business Line Data and Key Metrics Changes - North America net sales grew by 4%, with volume improving by 8%, driven by replacing lost volume from the previous year and new customer contracts [28][29] - International segment sales increased by 5%, with volume up by 12%, despite soft restaurant traffic in key markets [30] - Adjusted EBITDA for North America increased by $15 million to $301 million, while the international segment saw a decline of $8.5 million to $93 million [34] Market Data and Key Metrics Changes - QSR traffic in North America declined by 2% year-over-year, with hamburger chains experiencing a 6% drop in February [28][29] - The company anticipates a mid-single-digit percent decline in potato prices for the 2025 crop in North America, while prices in Europe are expected to remain flat [19][20] Company Strategy and Development Direction - The company is focusing on a value creation plan with the help of Alex Partners to optimize operations and drive growth [9][10] - Efforts include restructuring plans aimed at delivering at least $55 million in pre-tax savings for FY 2025 and $85 million for FY 2026 [12][51] - The company is committed to improving customer relations and expanding its product offerings to meet evolving customer needs [16][18] Management's Comments on Operating Environment and Future Outlook - Management noted that consumer uncertainty has increased, impacting restaurant traffic and overall demand [13][18] - The company expects continued pressure on pricing and margins due to competitive dynamics and inflationary costs [44][45] - Despite challenges, management remains optimistic about achieving full-year guidance and is focused on cost reduction and operational efficiency [46][47] Other Important Information - The company ended Q3 with approximately $1.1 billion in liquidity and a net debt of $4.2 billion, maintaining a leverage ratio of 3.4 times [35][36] - Capital expenditures for FY 2025 are targeted at $750 million, down from the previous year, with a focus on modernization and environmental investments [38][39] - The company returned $151 million to shareholders in the quarter, including $100 million in share repurchases [40] Q&A Session Summary Question: Impact of crop prices on QSR contract negotiations - Management indicated that customer contract negotiations will begin in the summer, and while potato prices are expected to decline, other inflationary impacts will also be considered [57][58] Question: Opportunities from Alex Partners agreement - The focus is on cost savings, productivity, and a data-driven approach to identify growth opportunities across the entire P&L [61][63] Question: Q4 gross margin expectations - Management explained that higher fixed cost absorption and other input costs will impact gross margins, with a forecasted decline of around 700 basis points [69][72] Question: Connell plant future plans - The company has decided not to sell the Connell plant and is conducting a strategic review of other options [100][101] Question: Weakness in QSR traffic - Management attributed the decline in QSR traffic to consumer uncertainty and macroeconomic factors, while noting that French fry attachment rates remain strong [108][119] Question: Changes in capital expenditures - Maintenance capital expenditures are about 3% of sales, with additional spending for modernization and environmental initiatives [136] Question: Competitive landscape in QSR contracts - The company is adjusting its contract schedule and is open to new ideas and innovations to drive traffic for QSRs [138][139]